Each year nearly 800,000 people in the U.S. experience a new or recurrent stroke, and every four minutes, someone dies from one.1 For those who survive, the road to recovery can be long and difficult.
The only FDA-approved drug currently available for ischemic stroke must be administered to the patient within three to four hours of the onset of the stroke. As a result, it is estimated that less than 5% of ischemic stroke victims currently receive this treatment.2
Regenerative therapies made of adult human stem cells have shown promise in Phase II clinical testing to not only protect damaged neurons and reduce inflammation, but to actually promote new blood vessel formation and augment tissue repair and healing. If approved, these therapies — unlike the other available options — could be administered long after a stroke has occurred with positive effects.
This is the promise of biologic innovation: that never settling will continue to improve outcomes and provide new options.